GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » FCF Margin %

Novelion Therapeutics (STU:QLTA) FCF Margin % : 25.31% (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is Novelion Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Novelion Therapeutics's Free Cash Flow for the three months ended in Mar. 2019 was €7.2 Mil. Novelion Therapeutics's Revenue for the three months ended in Mar. 2019 was €28.5 Mil. Therefore, Novelion Therapeutics's FCF Margin % for the quarter that ended in Mar. 2019 was 25.31%.

As of today, Novelion Therapeutics's current FCF Yield % is 0.00%.

The historical rank and industry rank for Novelion Therapeutics's FCF Margin % or its related term are showing as below:

STU:QLTA' s FCF Margin % Range Over the Past 10 Years
Min: -18.06   Med: 0   Max: 0
Current: -18.06

STU:QLTA's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -149.8 vs STU:QLTA: -18.06

Novelion Therapeutics FCF Margin % Historical Data

The historical data trend for Novelion Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novelion Therapeutics FCF Margin % Chart

Novelion Therapeutics Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -254.24 -40.20 -42.86

Novelion Therapeutics Quarterly Data
Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.46 -36.48 -39.93 -22.64 25.31

Competitive Comparison of Novelion Therapeutics's FCF Margin %

For the Biotechnology subindustry, Novelion Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novelion Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Novelion Therapeutics's FCF Margin % falls into.


Novelion Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Novelion Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2018 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2018 )/Revenue (A: Dec. 2018 )
=-49.144/114.65
=-42.86 %

Novelion Therapeutics's FCF Margin for the quarter that ended in Mar. 2019 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2019 )/Revenue (Q: Mar. 2019 )
=7.213/28.497
=25.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novelion Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (STU:QLTA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (STU:QLTA) » Definitions » FCF Margin %
Comparable Companies
DFFN TSXV:KLY TSXV:QPT ASX:PTX ROCO:4197 XSAT:WNT PTIX IST:RTALB TROV NOVN MATN LSE:TRX ASX:NYR ATOS TSXV:BCT JAGX TSX:CTX ROCO:6744 ACHV EMBI
Traded in Other Exchanges
N/A
Address
c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3
Website
http://www.novelion.com
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.